Early aggressive treatment approaches for multiple sclerosis
A Simpson, EM Mowry, SD Newsome - Current treatment options in …, 2021 - Springer
Purpose of review This review presents a comprehensive analysis of the current high-
efficacy disease-modifying therapies (DMTs) available for treatment of multiple sclerosis …
efficacy disease-modifying therapies (DMTs) available for treatment of multiple sclerosis …
Current knowledge on multiple sclerosis pathophysiology, disability progression assessment and treatment options, and the role of autologous hematopoietic stem …
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that
affects nearly 2.8 million people each year. MS distinguishes three main types: relapsing …
affects nearly 2.8 million people each year. MS distinguishes three main types: relapsing …
Deep grey matter injury in multiple sclerosis: a NAIMS consensus statement
Although multiple sclerosis has traditionally been considered a white matter disease,
extensive research documents the presence and importance of grey matter injury including …
extensive research documents the presence and importance of grey matter injury including …
Associations of sNfL with clinico‐radiological measures in a large MS population
ES Sotirchos, KC Fitzgerald, CM Singh… - Annals of Clinical …, 2023 - Wiley Online Library
Objective Evaluation of serum neurofilament light chain (sNfL), measured using high‐
throughput assays on widely accessible platforms in large, real‐world MS populations, is a …
throughput assays on widely accessible platforms in large, real‐world MS populations, is a …
Intrinsic and extrinsic mechanisms of thalamic pathology in multiple sclerosis
Objective Thalamic atrophy is among the earliest brain changes detected in patients with
multiple sclerosis (MS) and the degree of thalamic atrophy is a strong predictor of disability …
multiple sclerosis (MS) and the degree of thalamic atrophy is a strong predictor of disability …
Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS
Background: In multiple sclerosis (MS), thalamic integrity is affected directly by
demyelination and neuronal loss, and indirectly by gray/white matter lesions outside the …
demyelination and neuronal loss, and indirectly by gray/white matter lesions outside the …
Patterns of brain atrophy in recently-diagnosed relapsing-remitting multiple sclerosis
Recurrent neuroinflammation in relapsing-remitting MS (RRMS) is thought to lead to
neurodegeneration, resulting in progressive disability. Repeated magnetic resonance …
neurodegeneration, resulting in progressive disability. Repeated magnetic resonance …
Brain atrophy assessment in multiple sclerosis: technical–and subject-related barriers for translation to real-world application in individual subjects
R Zivadinov, A Tranquille, JA Reeves… - Expert Review of …, 2024 - Taylor & Francis
Introduction Brain atrophy is a well-established MRI outcome for predicting clinical
progression and monitoring treatment response in persons with multiple sclerosis (pwMS) at …
progression and monitoring treatment response in persons with multiple sclerosis (pwMS) at …
Thalamic atrophy predicts 5-year disability progression in multiple sclerosis
K Hänninen, M Viitala, T Paavilainen, JO Karhu… - Frontiers in …, 2020 - frontiersin.org
Purpose: Thalamus is among the first brain regions to become atrophic in multiple sclerosis
(MS). We studied whether thalamic atrophy predicts disability progression at 5 years in a …
(MS). We studied whether thalamic atrophy predicts disability progression at 5 years in a …
Myeloid cell-associated aromatic amino acid metabolism facilitates CNS myelin regeneration
Regulation of myeloid cell activity is critical for successful myelin regeneration
(remyelination) in demyelinating diseases, such as multiple sclerosis (MS). Here, we show …
(remyelination) in demyelinating diseases, such as multiple sclerosis (MS). Here, we show …